DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20162695

Cost variation study of antidepressant drugs

Ajay Kumar Shukla, Parag Sharma

Abstract


Background: Depression and anxiety disorders are the most common mental illnesses, each affecting in excess of 10-15% of the population at some time in their lives. Approximately 10-15% of those with severe depression attempt suicide at some point of time. Thus, it is important that symptoms of depression be recognized and treated appropriately.

Methods: The prices of 15 antidepressant drugs, available in 43 different formulations were analyzed. Costs of different brands of a particular generic antidepressant drug being manufactured by different companies, in the same strength and dosage forms were used to calculate cost ratio and percentage cost variation.

Results: This study shows that there is a wide variation in the prices of different brands of same antidepressant drug in Indian market. The highest cost ratio and percent cost variation was found for amitriptyline 50 mg, followed by bupropion 25 mg, amitriptyline 75 mg and dosulepin 50 mg. Highest number of brands of antidepressant drugs available in Indian market are for escitalopram 10 mg followed by escitalopram 5 mg and 20 mg.

Conclusions: There is wide price variation of different brands of the same generic antidepressant drug in Indian market. Cost of a drug plays an important role in treatment of depression as it follows a long course and adherence to the treatment is related with drug cost. To decrease the wide cost variation among different brands of antidepressant drugs; it is high time to generate physician awareness about impact of cost effectiveness of drug regimen and for regulation of drug prices by the concerned agencies.


Keywords


Cost analysis, Compliance, Adherence, Depression, Health Economics, Cost variation

Full Text:

PDF

References


O’ Donnell JM, Shelton RC. Drug therapy of depression and anxiety disorders. In: Brunton LB,Chabner BA, Knollman BC, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011:397-414.

Suominen KH, Isometsa ET, Henriksson MM, Ostamo AI, Lönnqvist JK. Inadequate treatment for major depression both before and after attempted suicide. Am J Psychiatry. 1998;155:1778-80.

Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry. 1996;39:896-9.

Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther. 2006;110:135-70

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psych. 2006;163:1905-17.

Shelton RC. Augmentation strategies to increase antidepressant efficacy. J Clin Psych. 2007;68(Suppl 10):18-22.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160‑3.

DiPiro JT, Lamber RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacoeconomics: Principles, Methods, and Applications. Pharmacotherapy: a Pathophysiologic Approach. 19e. New York, NY: McGraw-Hill; 2011:01.

Operational Guidelines on Free drug service Initiative. National Health Mission. Available at https://mpphscl.in/Files/PDF/b731acad-eded-43b6-b286-99aea308b1fb_0_Free_Drugs_Service_Intitiative.pdf. last accessed on 2016 July 22.

Gupta SK. Proposed Pharmacoeconomics Guidelines for India (PEG-I).IPSOR India Chapter;2013:79-100.

Akila L, Rani RJ. Cost analysis of different brands of antianginal drugs available in India. Int J Basic Clin Pharmacol. 2015;4:860-3.

Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: A systematic review. PLoS Med. 2007;4(9):e283.

Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-7.

National list of essential medicines 2015. Available at http://www.drugscontrol.org/pdf/NLEM-2015.pdf. Last accessed on 2016 July 22.

Ho PM, Bryson CL, Rumsfeld JS. Medication Adherence: Its Importance in Cardiovascular Outcomes. Circulation. 2009;119:3028-35.

Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How Patient cost-sharing trends affect adherence and outcomes: a literature review. Pharm Therapeut. 2012;37(1):45-55.

Creese A, Kotwani A, Kutzin J, Pillay A. Evaluating pharmaceuticals for health policy in low and middle income country settings. In: Freemantle N, Hill S, editors. Evaluating pharmaceuticals for health policy and reimbursement. Massachusetts, USA: Blackwell Publication; (in collaboration with WHO Geneva); 2004:227-43.

World Health Organisation. Essential drugs and medicines: Drug finance. Available at http://www.whoindia.org/EN/Section2/Section/Section160_959.html. Accessed 12 September 2014.

Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol 2011;43:131-6.

Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21.

Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India. Int J Basic Clin Pharmacol 2016;5(4):1636-40.

Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS et al. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015;52(Pt A):14-8.